Skip to main content
Journal cover image

Mitochondrial Dysfunction: Metabolic Drivers of Pulmonary Hypertension.

Publication ,  Journal Article
Suliman, HB; Nozik-Grayck, E
Published in: Antioxid Redox Signal
October 20, 2019

Significance: Pulmonary hypertension (PH) is a progressive disease characterized by pulmonary vascular remodeling and lung vasculopathy. The disease displays progressive dyspnea, pulmonary artery uncoupling and right ventricular (RV) dysfunction. The overall survival rate is ranging from 28-72%. Recent Advances: The molecular events that promote the development of PH are complex and incompletely understood. Metabolic impairment has been proposed to contribute to the pathophysiology of PH with evidence for mitochondrial dysfunction involving the electron transport chain proteins, antioxidant enzymes, apoptosis regulators, and mitochondrial quality control. Critical Issues: It is vital to characterize the mechanisms by which mitochondrial dysfunction contribute to PH pathogenesis. This review focuses on the currently available publications that supports mitochondrial mechanisms in PH pathophysiology. Future Directions: Further studies of these metabolic mitochondrial alterations in PH could be viable targets of diagnostic and therapeutic intervention.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Antioxid Redox Signal

DOI

EISSN

1557-7716

Publication Date

October 20, 2019

Volume

31

Issue

12

Start / End Page

843 / 857

Location

United States

Related Subject Headings

  • Signal Transduction
  • Oxidation-Reduction
  • Mitophagy
  • Mitochondria
  • Hypertension, Pulmonary
  • Humans
  • Disease Progression
  • Biochemistry & Molecular Biology
  • Animals
  • 3205 Medical biochemistry and metabolomics
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Suliman, H. B., & Nozik-Grayck, E. (2019). Mitochondrial Dysfunction: Metabolic Drivers of Pulmonary Hypertension. Antioxid Redox Signal, 31(12), 843–857. https://doi.org/10.1089/ars.2018.7705
Suliman, Hagir B., and Eva Nozik-Grayck. “Mitochondrial Dysfunction: Metabolic Drivers of Pulmonary Hypertension.Antioxid Redox Signal 31, no. 12 (October 20, 2019): 843–57. https://doi.org/10.1089/ars.2018.7705.
Suliman HB, Nozik-Grayck E. Mitochondrial Dysfunction: Metabolic Drivers of Pulmonary Hypertension. Antioxid Redox Signal. 2019 Oct 20;31(12):843–57.
Suliman, Hagir B., and Eva Nozik-Grayck. “Mitochondrial Dysfunction: Metabolic Drivers of Pulmonary Hypertension.Antioxid Redox Signal, vol. 31, no. 12, Oct. 2019, pp. 843–57. Pubmed, doi:10.1089/ars.2018.7705.
Suliman HB, Nozik-Grayck E. Mitochondrial Dysfunction: Metabolic Drivers of Pulmonary Hypertension. Antioxid Redox Signal. 2019 Oct 20;31(12):843–857.
Journal cover image

Published In

Antioxid Redox Signal

DOI

EISSN

1557-7716

Publication Date

October 20, 2019

Volume

31

Issue

12

Start / End Page

843 / 857

Location

United States

Related Subject Headings

  • Signal Transduction
  • Oxidation-Reduction
  • Mitophagy
  • Mitochondria
  • Hypertension, Pulmonary
  • Humans
  • Disease Progression
  • Biochemistry & Molecular Biology
  • Animals
  • 3205 Medical biochemistry and metabolomics